livertox

The recent revocation of Ulipristal licence for the indication of uterine fibroids has once again reminded the Pharmacovigilance community about the importance of Drug-induced liver injury, or DILI. Incidentally, DILI is one of the commonest reasons for product withdrawals. Drug-induced liver injury (DILI) is uncommon, but a potentially fatal, cause of a liver disease that […]